Butopamine
Pharmaceutical compound
From Wikipedia, the free encyclopedia
Butopamine (INN, USAN; developmental code name LY-131126; also known as (R,R)-ractopamine) is a sympathomimetic agent, β-adrenergic receptor agonist, and positive inotrope of the phenethylamine family which was studied for treatment of heart failure but was never marketed.[1][2][3][4] It is an analogue of dobutamine[3][4] and is the (R,R)-enantiomer of ractopamine.[2] Butopamine is not a catecholamine and is resistant to metabolism by catechol O-methyltransferase (COMT).[3] In contrast to dobutamine, butopamine is orally active.[3] In addition to its positive inotropic effects, butopamine has positive chronotropic effects.[3]
Other names
- LY-131126
- (R,R)-Ractopamine
| Clinical data | |
|---|---|
| Other names |
|
| Drug class | Sympathomimetic; β-Adrenergic receptor agonist; Positive inotrope; Positive chronotrope |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C18H23NO3 |
| Molar mass | 301.386 g·mol−1 |
| 3D model (JSmol) | |
| |
| |